Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Chem Biol Interact. 2019 Sep 30;314:108822. doi: 10.1016/j.cbi.2019.108822

Figure 3: GSEA of ALDH1A3hi and ALDH1A3lo cohorts in metastatic BRAF-mutant melanoma and ALDH1A1hi and ALDH1A1lo cohorts in metastatic BRAF WT melanoma.

Figure 3:

(A) Left, Differentially enriched HALLMARK gene sets between ALDH1A3hi (in red) and ALDH1A3lo (in blue) cohorts in metastatic BRAF-mutant melanoma. Right, Differentially enriched HALLMARK gene sets between ALDH1A1hi (in red) and ALDH1A1lo (in blue) cohorts in metastatic BRAF wild-type (WT) melanoma. (B) Comparison between gene sets enriched in ALDH1A3hi metastatic BRAF-mutant melanoma cohort (shown in Fig. 3A, left panel) and ALDH1A1hi metastatic BRAF WT melanoma cohort (shown in Fig. 3A, right panel). Shared gene sets are listed. (C) Comparison between gene sets enriched in ALDH1A3lo metastatic BRAF-mutant melanoma cohort (shown in Fig. 3A, left panel) and ALDH1A1lo metastatic BRAF WT melanoma cohort (shown in Fig. 3A, right panel). Shared gene sets are listed. Met-BRAF-mut 1A3, metastatic melanoma with BRAF mutation with hi (Fig. 3B) or lo (Fig. 3C) ALDH1A3; Met-BRAF WT 1A1, metastatic melanoma with WT BRAF with hi (Fig. 3B) or lo (Fig. 3C) ALDH1A1.